PMID: 8958955Oct 31, 1996Paper

Interleukin-12 alters helper T-cell subsets and antibody profiles induced by the mucosal adjuvant cholera toxin

Annals of the New York Academy of Sciences
M MarinaroJ R McGhee

Abstract

We have shown that systemic administration of rmIL-12 could trigger Th1-type responses to a protein antigen delivered orally with CT as mucosal adjuvant. The most striking finding was that IL-12 could retain its regulatory effects when orally administered and could redirect the immune response to the oral vaccine toward a Th1-type. However, regulation by orally administered IL-12 differed from parenteral treatment with IL-12 since only the latter treatment affected mucosal S-IgA responses. These findings have important implications for the development of mucosal vaccines that induce the desired immune response.

References

Dec 1, 1975·The Journal of Experimental Medicine·N F Pierce, J L Gowans
Mar 1, 1987·European Journal of Immunology·C O Elson, W Ealding
Jan 1, 1995·The Journal of Experimental Medicine·M VajdyN Lycke
Aug 1, 1994·Current Opinion in Immunology·H F StaatsJ R McGhee

❮ Previous
Next ❯

Citations

Jun 6, 2000·Advanced Drug Delivery Reviews·J W Simecka
Oct 3, 1999·Vaccine·M J McCluskie, H L Davis
May 22, 2001·AIDS Patient Care and STDs·A P Keaveny, M S Karasik
Oct 20, 1999·Methods : a Companion to Methods in Enzymology·M Rodolfo, M P Colombo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.